H Moses Murdock

16PUBLICATIONS
54CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCardiovascular medicine and haematology not elsewhere classifiedHaematologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

|Feb 02, 2026
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Shai Shimony, H Moses Murdock, Julia H Keating

|Dec 05, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

|Oct 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

|Dec 24, 2024
How I treat AML relapse after allogeneic HSCT.

Mahasweta Gooptu, H Moses Murdock, Robert J Soiffer

|Jan 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

Pageof 3

Frequent Collaborators

7 joint publications

R Coleman Lindsley

6 joint publications

Jacqueline S Garcia

3 joint publications

Marlise R Luskin

3 joint publications

Lukasz P Gondek